Home › Transplant Genomics And Quark Pharmaceuticals Announce Discovery And Development Collaboration
 

Keywords :   


Transplant Genomics And Quark Pharmaceuticals Announce Discovery And Development Collaboration

2016-04-15 03:46:09| drugdiscoveryonline Home Page

Transplant Genomics Inc. ("TGI") and Quark Pharmaceuticals, Inc. ("Quark") today announced their joint intent to pursue a discovery and development collaboration involving the use of TGI's TruGraf™ blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with Quark's proprietary drug candidate QPI-1002.

Tags: development collaboration discovery announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07High input costs, rising interest rates continue to weigh on farmer sentiment
03.07High input costs, rising interest rates continue to weigh on farmer sentiment
03.07EPAs PFAS Hazardous Substance Rule on the Horizon
03.07Sensory analysis shows pork has 111 unique flavor nuances
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 19A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07This Month in Waste: Top Stories for June 2024
More »